The Evolving Understanding and Approach to Residual Cardiovascular Risk Management

被引：122

作者：

Dhindsa, Devinder S. ^{[1
]}

Sandesara, Pratik B. ^{[1
]}

Shapiro, Michael D. ^{[2
]}

Wong, Nathan D. ^{[3
]}

机构：

[1] Emory Clin Cardiovasc Res Inst, Dept Med, Div Cardiol, Atlanta, GA 30322 USA

[2] Wake Forest Baptist Med Ctr, Ctr Prevent Cardiovasc Dis, Sect Cardiovasc Med, Winston Salem, NC USA

[3] Univ Calif Irvine, Div Cardiol, Heart Dis Prevent Program, Irvine, CA USA

来源：

FRONTIERS IN CARDIOVASCULAR MEDICINE | 2020年 / 7卷

关键词：

residual risk; secondary prevention; primary prevention; inflammation; cardiovascular risk factors; cardiovascular disease; atherosclerosis; metabolic syndrome; CORONARY-HEART-DISEASE; DENSITY-LIPOPROTEIN CHOLESTEROL; ALL-CAUSE MORTALITY; PHOSPHOLIPASE A(2); HDL CHOLESTEROL; EFFLUX CAPACITY; SECONDARY PREVENTION; CLONAL HEMATOPOIESIS; ENDOTHELIAL FUNCTION; REMNANT CHOLESTEROL;

D O I：

10.3389/fcvm.2020.00088

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Despite unprecedented advances in treatment of atherosclerotic cardiovascular disease, it remains the leading cause of death and disability worldwide. Treatment of major traditional risk factors, including low-density lipoprotein-cholesterol, serves as the foundation of atherosclerotic risk reduction. However, there remains a significant residual risk of cardiovascular events despite optimal risk factor management. Beyond traditional risk factors, other drivers of residual risk have come to the forefront, including inflammatory, pro-thrombotic, and metabolic pathways that contribute to recurrent events and are often unrecognized and not addressed in clinical practice. This review will explore the evidence linking these pathways to atherosclerotic cardiovascular disease and potential future therapeutic options to attenuate residual cardiovascular risk conferred by these pathways.

引用

页数：11

共 110 条

[1] Targeting Residual Inflammatory Risk: A Shifting Paradigm for Atherosclerotic Disease [J].

Aday, Aaron W. ;

Ridker, Paul M. .

FRONTIERS IN CARDIOVASCULAR MEDICINE, 2019, 6

[2] Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial [J].

Anand, Sonia S. ;

Bosch, Jackie ;

Eikelboom, John W. ;

Connolly, Stuart J. ;

Diaz, Rafael ;

Widimsky, Peter ;

Aboyans, Victor ;

Alings, Marco ;

Kakkar, Ajay K. ;

Keltai, Katalin ;

Maggioni, Aldo P. ;

Lewis, Basil S. ;

Stoerk, Stefan ;

Zhu, Jun ;

Lopez-Jaramillo, Patricio ;

O'Donnell, Martin ;

Commerford, Patrick J. ;

Vinereanu, Dragos ;

Pogosova, Nana ;

Ryden, Lars ;

Fox, Keith A. A. ;

Bhatt, Deepak L. ;

Misselwitz, Frank ;

Varigos, John D. ;

Vanassche, Thomas ;

Avezum, Alvaro A. ;

Chen, Edmond ;

Branch, Kelley ;

Leong, Darryl P. ;

Bangdiwala, Shrikant I. ;

Hart, Robert G. ;

Yusuf, Salim .

LANCET, 2018, 391 (10117) :219-229

[3] The relationships between post-prandial lipaemia, endothelial function and oxidative stress in healthy individuals and patients with type 2 diabetes [J].

Anderson, RA ;

Evans, ML ;

Ellis, GR ;

Graham, J ;

Morris, K ;

Jackson, SK ;

Lewis, MJ ;

Rees, A ;

Frenneaux, MP .

ATHEROSCLEROSIS, 2001, 154 (02) :475-483

[4] Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials [J].

Baigent, C. ;

Blackwell, L. ;

Emberson, J. ;

Holland, L. E. ;

Reith, C. ;

Bhala, N. ;

Peto, R. ;

Barnes, E. H. ;

Keech, A. ;

Simes, J. ;

Collins, R. .

LANCET, 2010, 376 (9753) :1670-1681

[5] Effects of torcetrapib in patients at high risk for coronary events [J].

Barter, Philip J. ;

Caulfield, Mark ;

Eriksson, Mats ;

Grundy, Scott M. ;

Kastelein, John J. P. ;

Komajda, Michel ;

Lopez-Sendon, Jose ;

Mosca, Lori ;

Tardif, Jean-Claude ;

Waters, David D. ;

Shear, Charles L. ;

Revkin, James H. ;

Buhr, Kevin A. ;

Fisher, Marian R. ;

Tall, Alan R. ;

Brewer, Bryan .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (21) :2109-2122

[6] Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial [J].

Bhatt, Deepak L. ;

Steg, Philippe Gabriel ;

Mehta, Shamir R. ;

Leiter, Lawrence A. ;

Simon, Tabassome ;

Fox, Kim ;

Held, Claes ;

Andersson, Marielle ;

Himmelmann, Anders ;

Ridderstrale, Wilhelm ;

Chen, Jersey ;

Song, Yang ;

Diaz, Rafael ;

Goto, Shinya ;

James, Stefan K. ;

Ray, Kausik K. ;

Parkhomenko, Alexander N. ;

Kosiborod, Mikhail N. ;

McGuire, Darren K. ;

Harrington, Robert A. .

LANCET, 2019, 394 (10204) :1169-1180

[7] Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia [J].

Bhatt, Deepak L. ;

Steg, P. Gabriel ;

Miller, Michael ;

Brinton, Eliot A. ;

Jacobson, Terry A. ;

Ketchum, Steven B. ;

Doyle, Ralph T., Jr. ;

Juliano, Rebecca A. ;

Jiao, Lixia ;

Granowitz, Craig ;

Tardif, Jean-Claude ;

Ballantyne, Christie M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (01) :11-22

[8] Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome [J].

Bittner, Vera A. ;

Szarek, Michael ;

Aylward, Philip E. ;

Bhatt, Deepak L. ;

Diaz, Rafael ;

Edelberg, Jay M. ;

Fras, Zlatko ;

Goodman, Shaun G. ;

Halvorsen, Sigrun ;

Hanotin, Corinne ;

Harrington, Robert A. ;

Jukema, J. Wouter ;

Loizeau, Virginie ;

Moriarty, Patrick M. ;

Moryusef, Angele ;

Pordy, Robert ;

Roe, Matthew T. ;

Sinnaeve, Peter ;

Tsimikas, Sotirios ;

Vogel, Robert ;

White, Harvey D. ;

Zahger, Doron ;

Zeiher, Andreas M. ;

Steg, Gabriel ;

Schwartz, Gregory G. ;

Aylward, Philip E. ;

Drexel, Heinz ;

Sinnaeve, Peter ;

Dilic, Mirza ;

Lopes, Renato D. ;

Gotcheva, Nina N. ;

Prieto, Juan-Carlos ;

Yong, Huo ;

Lopez-Jaramillo, Patricio ;

Pecin, Ivan ;

Reiner, Zeljko ;

Ostadal, Petr ;

Poulsen, Steen Hvitfeldt ;

Viigimaa, Margus ;

Nieminen, Markku S. ;

Danchin, Nicolas ;

Chumburidze, Vakhtang ;

Marx, Nikolaus ;

Liberopoulos, Evangelos ;

Montenegro Valdovinos, Pablo Carlos ;

Tse, Hung-Fat ;

Kiss, Robert Gabor ;

Xavier, Denis ;

Zahger, Doron ;

Valgimigli, Marco .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (02) :133-144

[9] Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy [J].

Boden, William E. ;

Probstfield, Jeffrey L. ;

Anderson, Todd ;

Chaitman, Bernard R. ;

Desvignes-Nickens, Patrice ;

Koprowicz, Kent ;

McBride, Ruth ;

Teo, Koon ;

Weintraub, William .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (24) :2255-2267

[10] Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction [J].

Bonaca, Marc P. ;

Bhatt, Deepak L. ;

Cohen, Marc ;

Steg, Philippe Gabriel ;

Storey, Robert F. ;

Jensen, Eva C. ;

Magnani, Giulia ;

Bansilal, Sameer ;

Fish, M. Polly ;

Im, Kyungah ;

Bengtsson, Olof ;

Ophuis, Ton Oude ;

Budaj, Andrzej ;

Theroux, Pierre ;

Ruda, Mikhail ;

Hamm, Christian ;

Goto, Shinya ;

Spinar, Jindrich ;

Nicolau, Jose Carlos ;

Kiss, Robert G. ;

Murphy, Sabina A. ;

Wiviott, Stephen D. ;

Held, Peter ;

Braunwald, Eugene ;

Sabatine, Marc S. ;

Morin, Suzanne ;

Dantzer, Emily ;

Acquilano, Dayle ;

McGuire, Rachael L. ;

Gannon, Joseph B. ;

Gershman, Elaine ;

Ahlbom, Ann Maxe ;

Boberg, Barbro ;

Abola, Maria Teresa ;

Ardissino, Diego ;

Aylward, Philip ;

Corbalan, Ramon ;

Dalby, Anthony ;

Diaz, Rafael ;

Hu, Dayi ;

Isaza, Daniel ;

Kamensky, Gabriel ;

Kiss, Robert ;

Kontny, Frederic ;

Lopez-Sendon, Jose ;

Medina, Felix ;

Montalescot, Gilles ;

Nicolau, Jose ;

Paolasso, Ernesto ;

Parkhomenko, Alexander .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (19) :1791-1800

← 1 2 3 4 5 6 7 8 9 10 →